Ligand Pharma-Roche CVRLGNDZPreferred / convertible
13F holders, Q2 2025 (June 30)1holders
1new positions
0sold out
$0.00avg. 13F price*
At the end of Q2 2025, 1 institutions reported holding Ligand Pharma-Roche CVR (LGNDZ) in their 13F filings, unchanged from Q4 2024. 1 opened new positions and 0 sold out. The largest holder was Ancora Advisors LLC ($30).
- Company
- Ligand Pharma-Roche CVR
- CUSIP
- 53220K215
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $30 |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q2 2025: 12,000 shares bought, net +12,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Ancora Advisors LLC | — | New | 12,000 | $30 |
"% of holder's portfolio" is LGNDZ's weight in each manager's 13F, not the share of Ligand Pharma-Roche CVR the manager owns.